Long-term efficacy of triple oral therapy for type 2 diabetes mellitus

Endocrine Practice

Volumn 8, Issue 4, 2002, Pages 271-275

  Bell, David S H ^a   Ovalle, Fernando ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; C PEPTIDE; GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA; 2,4 THIAZOLIDINEDIONE; 2,4-THIAZOLIDINEDIONE; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; SULFONYLUREA DERIVATIVE; THIAZOLE DERIVATIVE;

ADULT; AGE; ARTICLE; BLOOD GLUCOSE MONITORING; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA ANALYSIS; DISEASE DURATION; DRUG EFFICACY; DRUG RESPONSE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RELEASE; LABORATORY TEST; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTION; TREATMENT OUTCOME; WEIGHT GAIN; ADOLESCENT; BLOOD; DRUG COMBINATION; MIDDLE AGED; TIME;

ADOLESCENT; ADULT; BODY MASS INDEX; C-PEPTIDE; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; METFORMIN; MIDDLE AGED; SULFONYLUREA COMPOUNDS; THIAZOLES; THIAZOLIDINEDIONES; TIME FACTORS; WEIGHT GAIN;

EID: 0036023909     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP.8.4.271     Document Type: Article

References (20)

1. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus
2. Outcome of metformin-facilitated reinitiation of oral diabetic therapy in insulin-treated patients with non-insulin-dependent diabetes mellitus
3. Improved glycemic control with use of oral hypoglycemic therapy with or without insulin
4. Weight loss in patients with diabetes treated with a metformin-sulfonylurea combination in comparison with twice-daily mixed insulin
5. How long can insulin be avoided in the patient with type 2 diabetes mellitus by use of a combination of metformin and a sulfonylurea?
6. Is avoiding insulin therapy an achievable and worthwhile goal?
7. Triple oral antidiabetic therapy in type 2 diabetes mellitus
8. Evaluation of a fully automated high-performance liquid chromatography assay for hemoglobin Alc
9. Automated chemiluminescent assay for C-peptide
10. Conversion from troglitazone to rosiglitazone
11. Clinical evidence of thiazolidinedione-induced improvement of pancreatic beta-cell function in patients with type 2 diabetes mellitus
12. Beta-cell mass dynamics in Zucker diabetic fatty rats: Rosiglitazone prevents the rise in net cell death
13. Rosiglitazone improves beta cell function as measured by proinsulin/insulin ratio in patients with type 2 diabetes
14. Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: A randomized, controlled study
15. Troglitazone lowers islet fat and restores beta cell function of Zucker diabetic fatty rats
16. Pancreatic beta-cells in obesity: Evidence for induction of functional, morphologic, and metabolic abnormalities by increased long chain fatty acids
17. Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: Impairment in adipocyte-beta-cell relationships
18. Poor glycaemic control in type 2 diabetes: A conspiracy of disease, suboptimal therapy and attitude
19. Effect of troglitazone on body fat distribution in type 2 diabetic patients
20. Pharmacologic therapy for type 2 diabetes mellitus